Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 197

1.

Respiratory syncytial virus nonstructural protein 1 downregulates glucocorticoid receptor expression through miR-29a.

Gao L, Mo S, Xie J, Chen S, Wen X, Long X, Ren L, Zang N, Xie X, Deng Y, Luo J, Luo Z, Fu Z, Smyth RL, Liu E.

J Allergy Clin Immunol. 2019 Sep;144(3):854-857.e6. doi: 10.1016/j.jaci.2019.05.014. Epub 2019 May 22. No abstract available.

PMID:
31128120
2.
3.

17q21 variant increases the risk of exacerbations in asthmatic children despite inhaled corticosteroids use.

Farzan N, Vijverberg SJ, Hernandez-Pacheco N, Bel EHD, Berce V, Bønnelykke K, Bisgaard H, Burchard EG, Canino G, Celedón JC, Chew FT, Chiang WC, Cloutier MM, Forno E, Francis B, Hawcutt DB, Herrera-Luis E, Kabesch M, Karimi L, Melén E, Mukhopadhyay S, Merid SK, Palmer CN, Pino-Yanes M, Pirmohamed M, Potočnik U, Repnik K, Schieck M, Sevelsted A, Sio YY, Smyth RL, Soares P, Söderhäll C, Tantisira KG, Tavendale R, Tse SM, Turner S, Verhamme KM, Maitland-van der Zee AH.

Allergy. 2018 Oct;73(10):2083-2088. doi: 10.1111/all.13499. Epub 2018 Jul 9. No abstract available.

4.

An in vitro transepithelial migration assay to evaluate the role of neutrophils in Respiratory Syncytial Virus (RSV) induced epithelial damage.

Deng Y, Herbert JA, Smith CM, Smyth RL.

Sci Rep. 2018 Apr 30;8(1):6777. doi: 10.1038/s41598-018-25167-4.

5.

Urinary Biomarkers of Aminoglycoside-Induced Nephrotoxicity in Cystic Fibrosis: Kidney Injury Molecule-1 and Neutrophil Gelatinase-Associated Lipocalin.

McWilliam SJ, Antoine DJ, Jorgensen AL, Smyth RL, Pirmohamed M.

Sci Rep. 2018 Mar 23;8(1):5094. doi: 10.1038/s41598-018-23466-4.

6.

Susceptibility to corticosteroid-induced adrenal suppression: a genome-wide association study.

Hawcutt DB, Francis B, Carr DF, Jorgensen AL, Yin P, Wallin N, O'Hara N, Zhang EJ, Bloch KM, Ganguli A, Thompson B, McEvoy L, Peak M, Crawford AA, Walker BR, Blair JC, Couriel J, Smyth RL, Pirmohamed M.

Lancet Respir Med. 2018 Jun;6(6):442-450. doi: 10.1016/S2213-2600(18)30058-4. Epub 2018 Mar 15.

7.

Ursodeoxycholic acid for cystic fibrosis-related liver disease.

Cheng K, Ashby D, Smyth RL.

Cochrane Database Syst Rev. 2017 Sep 11;9:CD000222. doi: 10.1002/14651858.CD000222.pub4. Review.

8.

Rationale and design of the multiethnic Pharmacogenomics in Childhood Asthma consortium.

Farzan N, Vijverberg SJ, Andiappan AK, Arianto L, Berce V, Blanca-López N, Bisgaard H, Bønnelykke K, Burchard EG, Campo P, Canino G, Carleton B, Celedón JC, Chew FT, Chiang WC, Cloutier MM, Daley D, Den Dekker HT, Dijk FN, Duijts L, Flores C, Forno E, Hawcutt DB, Hernandez-Pacheco N, de Jongste JC, Kabesch M, Koppelman GH, Manolopoulos VG, Melén E, Mukhopadhyay S, Nilsson S, Palmer CN, Pino-Yanes M, Pirmohamed M, Potočnik U, Raaijmakers JA, Repnik K, Schieck M, Sio YY, Smyth RL, Szalai C, Tantisira KG, Turner S, van der Schee MP, Verhamme KM, Maitland-van der Zee AH.

Pharmacogenomics. 2017 Jul;18(10):931-943. doi: 10.2217/pgs-2017-0035. Epub 2017 Jun 22.

9.

Oral calorie supplements for cystic fibrosis.

Smyth RL, Rayner O.

Cochrane Database Syst Rev. 2017 May 4;5:CD000406. doi: 10.1002/14651858.CD000406.pub5. Review.

10.

Development of the Liverpool Adverse Drug Reaction Avoidability Assessment Tool.

Bracken LE, Nunn AJ, Kirkham JJ, Peak M, Arnott J, Smyth RL, Pirmohamed M, Turner MA.

PLoS One. 2017 Jan 3;12(1):e0169393. doi: 10.1371/journal.pone.0169393. eCollection 2017.

11.

A survey of facilitators and barriers to recruitment to the MAGNETIC trial.

Kaur G, Smyth RL, Powell CV, Williamson P.

Trials. 2016 Dec 23;17(1):607. doi: 10.1186/s13063-016-1724-3.

12.

Aminoglycoside-induced nephrotoxicity in children.

McWilliam SJ, Antoine DJ, Smyth RL, Pirmohamed M.

Pediatr Nephrol. 2017 Nov;32(11):2015-2025. doi: 10.1007/s00467-016-3533-z. Epub 2016 Nov 15. Review.

13.

Getting paediatric clinical trials published.

Smyth RL.

Lancet. 2016 Nov 12;388(10058):2333-2334. doi: 10.1016/S0140-6736(16)32125-0. No abstract available.

PMID:
27845080
14.

Questioning assent: how are children's views included as families make decisions about clinical trials?

Madden L, Shilling V, Woolfall K, Sowden E, Smyth RL, Williamson PR, Young B.

Child Care Health Dev. 2016 Nov;42(6):900-908. doi: 10.1111/cch.12347. Epub 2016 May 2.

15.

Adrenal responses to a low-dose short synacthen test in children with asthma.

Hawcutt DB, Jorgensen AL, Wallin N, Thompson B, Peak M, Lacy D, Newland P, Didi M, Couriel J, Blair J, Pirmohamed M, Smyth RL.

Clin Endocrinol (Oxf). 2016 May;84(5):793. doi: 10.1111/cen.13069. No abstract available.

PMID:
27043153
16.

Diel Surface Temperature Range Scales with Lake Size.

Woolway RI, Jones ID, Maberly SC, French JR, Livingstone DM, Monteith DT, Simpson GL, Thackeray SJ, Andersen MR, Battarbee RW, DeGasperi CL, Evans CD, de Eyto E, Feuchtmayr H, Hamilton DP, Kernan M, Krokowski J, Rimmer A, Rose KC, Rusak JA, Ryves DB, Scott DR, Shilland EM, Smyth RL, Staehr PA, Thomas R, Waldron S, Weyhenmeyer GA.

PLoS One. 2016 Mar 29;11(3):e0152466. doi: 10.1371/journal.pone.0152466. eCollection 2016.

17.

Oral steroids for long-term use in cystic fibrosis.

Cheng K, Ashby D, Smyth RL.

Cochrane Database Syst Rev. 2015 Dec 9;(12):CD000407. doi: 10.1002/14651858.CD000407.pub4. Review.

PMID:
26649765
18.

Comparing the harmful effects of nontuberculous mycobacteria and Gram negative bacteria on lung function in patients with cystic fibrosis.

Qvist T, Taylor-Robinson D, Waldmann E, Olesen HV, Hansen CR, Mathiesen IH, Høiby N, Katzenstein TL, Smyth RL, Diggle PJ, Pressler T.

J Cyst Fibros. 2016 May;15(3):380-5. doi: 10.1016/j.jcf.2015.09.007. Epub 2015 Oct 9.

19.

A pilot randomised controlled trial to assess the utility of an e-learning package that trains users in adverse drug reaction causality.

Conroy EJ, Kirkham JJ, Bellis JR, Peak M, Smyth RL, Williamson PR, Pirmohamed M.

Int J Pharm Pract. 2015 Dec;23(6):447-55. doi: 10.1111/ijpp.12197. Epub 2015 May 29.

20.

Challenges and opportunities in developing respiratory syncytial virus therapeutics.

Simões EA, DeVincenzo JP, Boeckh M, Bont L, Crowe JE Jr, Griffiths P, Hayden FG, Hodinka RL, Smyth RL, Spencer K, Thirstrup S, Walsh EE, Whitley RJ.

J Infect Dis. 2015 Mar 15;211 Suppl 1:S1-S20. doi: 10.1093/infdis/jiu828.

21.

ADRIC: Adverse Drug Reactions In Children – a programme of research using mixed methods.

Smyth RL, Peak M, Turner MA, Nunn AJ, Williamson PR, Young B, Arnott J, Bellis JR, Bird KA, Bracken LE, Conroy EJ, Cresswell L, Duncan JC, Gallagher RM, Gargon E, Hesselgreaves H, Kirkham JJ, Mannix H, Smyth RMD, Thiesen S, Pirmohamed M.

Southampton (UK): NIHR Journals Library; 2014 Jun.

22.

Comparing cystic fibrosis outcomes across the pond.

Taylor-Robinson DC, Schechter MS, Smyth RL.

Thorax. 2015 Mar;70(3):203-4. doi: 10.1136/thoraxjnl-2014-206393. Epub 2014 Dec 23. No abstract available.

23.

Ursodeoxycholic acid for cystic fibrosis-related liver disease.

Cheng K, Ashby D, Smyth RL.

Cochrane Database Syst Rev. 2014 Dec 15;(12):CD000222. doi: 10.1002/14651858.CD000222.pub3. Review. Update in: Cochrane Database Syst Rev. 2017 Sep 11;9:CD000222.

PMID:
25501301
24.

A biodiversity indicators dashboard: addressing challenges to monitoring progress towards the Aichi biodiversity targets using disaggregated global data.

Han X, Smyth RL, Young BE, Brooks TM, Sánchez de Lozada A, Bubb P, Butchart SH, Larsen FW, Hamilton H, Hansen MC, Turner WR.

PLoS One. 2014 Nov 19;9(11):e112046. doi: 10.1371/journal.pone.0112046. eCollection 2014.

25.

Adrenal responses to a low-dose short synacthen test in children with asthma.

Hawcutt DB, Jorgensen AL, Wallin N, Thompson B, Peak M, Lacy D, Newland P, Didi M, Couriel J, Blair J, Pirmohamed M, Smyth RL.

Clin Endocrinol (Oxf). 2015 May;82(5):648-56. doi: 10.1111/cen.12655. Epub 2014 Dec 22. Erratum in: Clin Endocrinol (Oxf). 2016 May;84(5):793.

PMID:
25378183
26.

Oral calorie supplements for cystic fibrosis.

Smyth RL, Rayner O.

Cochrane Database Syst Rev. 2014 Nov 3;(11):CD000406. doi: 10.1002/14651858.CD000406.pub4. Review. Update in: Cochrane Database Syst Rev. 2017 May 04;5:CD000406.

PMID:
25363148
27.

Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects.

Hawcutt DB, Ghani AA, Sutton L, Jorgensen A, Zhang E, Murray M, Michael H, Peart I, Smyth RL, Pirmohamed M.

Pharmacogenomics J. 2014 Dec;14(6):542-8. doi: 10.1038/tpj.2014.31. Epub 2014 Jul 8.

28.

Reference intervals for urinary renal injury biomarkers KIM-1 and NGAL in healthy children.

McWilliam SJ, Antoine DJ, Sabbisetti V, Pearce RE, Jorgensen AL, Lin Y, Leeder JS, Bonventre JV, Smyth RL, Pirmohamed M.

Biomark Med. 2014;8(10):1189-97. doi: 10.2217/bmm.14.36.

29.

Vaccines for preventing influenza in people with cystic fibrosis.

Dharmaraj P, Smyth RL.

Cochrane Database Syst Rev. 2014 Mar 6;(3):CD001753. doi: 10.1002/14651858.CD001753.pub3. Review.

PMID:
24604671
30.

The effect of social deprivation on clinical outcomes and the use of treatments in the UK cystic fibrosis population: a longitudinal study.

Taylor-Robinson DC, Smyth RL, Diggle PJ, Whitehead M.

Lancet Respir Med. 2013 Apr;1(2):121-8. doi: 10.1016/S2213-2600(13)70002-X. Epub 2013 Jan 30.

31.

Adverse drug reactions and off-label and unlicensed medicines in children: a nested case-control study of inpatients in a pediatric hospital.

Bellis JR, Kirkham JJ, Thiesen S, Conroy EJ, Bracken LE, Mannix HL, Bird KA, Duncan JC, Peak M, Turner MA, Smyth RL, Nunn AJ, Pirmohamed M.

BMC Med. 2013 Nov 7;11:238. doi: 10.1186/1741-7015-11-238.

32.

Incidence, characteristics and risk factors of adverse drug reactions in hospitalized children - a prospective observational cohort study of 6,601 admissions.

Thiesen S, Conroy EJ, Bellis JR, Bracken LE, Mannix HL, Bird KA, Duncan JC, Cresswell L, Kirkham JJ, Peak M, Williamson PR, Nunn AJ, Turner MA, Pirmohamed M, Smyth RL.

BMC Med. 2013 Nov 7;11:237. doi: 10.1186/1741-7015-11-237.

33.

Parents' agendas in paediatric clinical trial recruitment are different from researchers' and often remain unvoiced: a qualitative study.

Woolfall K, Shilling V, Hickey H, Smyth RL, Sowden E, Williamson PR, Young B.

PLoS One. 2013 Jul 3;8(7):e67352. doi: 10.1371/journal.pone.0067352. Print 2013.

34.

Oral steroids for long-term use in cystic fibrosis.

Cheng K, Ashby D, Smyth RL.

Cochrane Database Syst Rev. 2013 Jun 24;(6):CD000407. doi: 10.1002/14651858.CD000407.pub3. Review. Update in: Cochrane Database Syst Rev. 2015;(12):CD000407.

PMID:
23794322
35.

Adverse drug reactions causing admission to a paediatric hospital.

Gallagher RM, Mason JR, Bird KA, Kirkham JJ, Peak M, Williamson PR, Nunn AJ, Turner MA, Pirmohamed M, Smyth RL.

PLoS One. 2012;7(12):e50127. doi: 10.1371/journal.pone.0050127. Epub 2012 Dec 4.

36.

Paediatric pharmacogenomics: an overview.

Hawcutt DB, Thompson B, Smyth RL, Pirmohamed M.

Arch Dis Child. 2013 Mar;98(3):232-7. doi: 10.1136/archdischild-2012-302852. Epub 2012 Nov 29. Review.

PMID:
23196740
37.

Developing a survey of barriers and facilitators to recruitment in randomized controlled trials.

Kaur G, Smyth RL, Williamson P.

Trials. 2012 Nov 21;13:218. doi: 10.1186/1745-6215-13-218.

38.

Oral calorie supplements for cystic fibrosis.

Smyth RL, Walters S.

Cochrane Database Syst Rev. 2012 Oct 17;10:CD000406. doi: 10.1002/14651858.CD000406.pub3. Review. Update in: Cochrane Database Syst Rev. 2014;11:CD000406.

PMID:
23076887
39.

Ursodeoxycholic acid for cystic fibrosis-related liver disease.

Cheng K, Ashby D, Smyth RL.

Cochrane Database Syst Rev. 2012 Oct 17;10:CD000222. doi: 10.1002/14651858.CD000222.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;12:CD000222.

PMID:
23076885
40.

Enhancing communication about paediatric medicines: lessons from a qualitative study of parents' experiences of their child's suspected adverse drug reaction.

Arnott J, Hesselgreaves H, Nunn AJ, Peak M, Pirmohamed M, Smyth RL, Turner MA, Young B.

PLoS One. 2012;7(10):e46022. doi: 10.1371/journal.pone.0046022. Epub 2012 Oct 10.

41.

Respiratory syncytial virus infection of airway epithelial cells, in vivo and in vitro, supports pulmonary antibody responses by inducing expression of the B cell differentiation factor BAFF.

McNamara PS, Fonceca AM, Howarth D, Correia JB, Slupsky JR, Trinick RE, Al Turaiki W, Smyth RL, Flanagan BF.

Thorax. 2013 Jan;68(1):76-81. doi: 10.1136/thoraxjnl-2012-202288. Epub 2012 Sep 21.

PMID:
23002173
42.

Mechanism-based urinary biomarkers to identify the potential for aminoglycoside-induced nephrotoxicity in premature neonates: a proof-of-concept study.

McWilliam SJ, Antoine DJ, Sabbisetti V, Turner MA, Farragher T, Bonventre JV, Park BK, Smyth RL, Pirmohamed M.

PLoS One. 2012;7(8):e43809. doi: 10.1371/journal.pone.0043809. Epub 2012 Aug 24.

43.

What can we learn from parents about enhancing participation in pharmacovigilance?

Arnott J, Hesselgreaves H, Nunn AJ, Peak M, Pirmohamed M, Smyth RL, Turner MA, Young B.

Br J Clin Pharmacol. 2013 Apr;75(4):1109-17. doi: 10.1111/j.1365-2125.2012.04441.x.

44.

Standard 5: selection, measurement, and reporting of outcomes in clinical trials in children.

Sinha IP, Altman DG, Beresford MW, Boers M, Clarke M, Craig J, Alberighi OD, Fernandes RM, Hartling L, Johnston BC, Lux A, Plint A, Tugwell P, Turner M, van der Lee JH, Offringa M, Williamson PR, Smyth RL; StaR Child Health Group.

Pediatrics. 2012 Jun;129 Suppl 3:S146-52. doi: 10.1542/peds.2012-0055H. Review. No abstract available.

PMID:
22661761
45.

Development of a core outcome set for clinical trials in childhood asthma: a survey of clinicians, parents, and young people.

Sinha IP, Gallagher R, Williamson PR, Smyth RL.

Trials. 2012 Jul 2;13:103. doi: 10.1186/1745-6215-13-103.

46.

Understanding the natural progression in %FEV1 decline in patients with cystic fibrosis: a longitudinal study.

Taylor-Robinson D, Whitehead M, Diderichsen F, Olesen HV, Pressler T, Smyth RL, Diggle P.

Thorax. 2012 Oct;67(10):860-6. doi: 10.1136/thoraxjnl-2011-200953. Epub 2012 May 3.

47.

Paediatric use of mycophenolate mofetil.

Downing HJ, Pirmohamed M, Beresford MW, Smyth RL.

Br J Clin Pharmacol. 2013 Jan;75(1):45-59. doi: 10.1111/j.1365-2125.2012.04305.x. Review.

48.

IFITM3 restricts the morbidity and mortality associated with influenza.

Everitt AR, Clare S, Pertel T, John SP, Wash RS, Smith SE, Chin CR, Feeley EM, Sims JS, Adams DJ, Wise HM, Kane L, Goulding D, Digard P, Anttila V, Baillie JK, Walsh TS, Hume DA, Palotie A, Xue Y, Colonna V, Tyler-Smith C, Dunning J, Gordon SB; GenISIS Investigators; MOSAIC Investigators, Smyth RL, Openshaw PJ, Dougan G, Brass AL, Kellam P.

Nature. 2012 Mar 25;484(7395):519-23. doi: 10.1038/nature10921.

49.

Development and inter-rater reliability of the Liverpool adverse drug reaction causality assessment tool.

Gallagher RM, Kirkham JJ, Mason JR, Bird KA, Williamson PR, Nunn AJ, Turner MA, Smyth RL, Pirmohamed M.

PLoS One. 2011;6(12):e28096. doi: 10.1371/journal.pone.0028096. Epub 2011 Dec 14.

50.

A risk adapted approach to the governance of clinical trials.

Smyth RL.

BMJ. 2011 Oct 25;343:d6756. doi: 10.1136/bmj.d6756. No abstract available.

PMID:
22028486

Supplemental Content

Loading ...
Support Center